News Releases

//News Releases
News Releases 2017-08-15T10:45:58+00:00

News Releases

UbiVac CEO to Address FDA/AACR Workshop on Oncology Dosing and Participate in Congressional Briefing

July 16, 2017

Washington D.C. – UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder and CEO, Bernard A. Fox, PhD, will speak on July 20 at a workshop in the Capitol organized by the US Food & Drug Administration (FDA) and the American Association for Cancer Research (AACR). On July 19 Dr. Fox will speak at a US congressional briefing organized by AACR and the Society for Immunotherapy of Cancer (SITC), entitled Progress in Immuno-Oncology: Delivering Hope and Clinical Benefit to Cancer Patients.

According to Dr. Fox the FDA-AACR meeting has special significance for wider use of combination cancer immuno-therapies and will focus on approaches to combination therapy and best practices regarding patient and dose selection, biomarkers to aid in selection, and novel endpoints that can define patient benefit.

“The FDA is being proactive and working with academic and industry partners to discuss the role of biomarkers in patient selection and, in the case of combination studies to identify how to demonstrate the contribution that each agent has to a combination immunotherapy. In UbiVac’s case, where we will combine DPV-001 with co-stimulatory and checkpoint agents, this relates to our data obtained from patients receiving adjuvant treatment with DPV-001 alone.”

Dr. Fox, is a past president of SITC, chair of the World Immunotherapy Council and an internationally recognized expert in cancer immunotherapy.

###

Contact: Patricia Pearson, ppearson@ubivac.com

Award Number R44CA121612 from the National Cancer Institute supports the research and clinical trial of DPV-001 in patients with NSCLC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 recently completed a Phase II randomized multi-center adjuvant study for non-small cell lung cancer that documented efficacy for induction or boosting of broad anti-cancer immunity. Based on these data UbiVac is planning to open a phase Ib/II study of DPV-001 + anti-OX40 in patients with advanced cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.

By | July 30th, 2017|Categories: News Releases, Press|0 Comments

UbiVac Announces Positive Results of Phase II Adjuvant Clinical Trial

June 2, 2017

Chicago, Il. — UbiVac, www.ubivac.com, announced the results of their randomized phase II adjuvant clinical trial in patients with definitively-treated Stage III non-small cell lung cancer (NSCLC). Their data document the ability of UbiVac’s DRibble® cancer vaccine, DPV-001, to expand T cell clones and correlates with induction of immunity against a spectrum of non-small cell lung cancer antigens. While controversial, many experts agree that the absence of anti-cancer immunity is the major roadblock to increasing the proportion of patients who respond to immunotherapy. This study, in patients at high risk of disease recurrence, provides compelling evidence that the DRibble® cancer vaccine, DPV-001, induces and/or augments anti-cancer immunity and provides a strategy to increase objective response rates by combining UbiVac’s patented DRibble® vaccine technology with checkpoint blockade and/or T cell agonist antibody-based therapies.

Rachel Sanborn, M.D., the Principal investigator for the US National Cancer Institute (NCI)-supported study, was senior author for the study that was published in the American Society for Clinical Oncology (ASCO) 2017 meeting abstracts.  The results show that patients receiving DPV-001 had a significant (p<0.04) increase in total (CD4 + CD8) TCRs that increased 10-fold over baseline compared to normal controls and the increase in CD4 clones was similar to that seen following Ipilimumab.

“Based on these data, and building on preclinical data published last November in Scientific Reports – Nature, showing significant improvements in response and survival in animals receiving the combination of a DRibble® cancer vaccine plus anti-OX40, UbiVac is moving forward with a combination clinical trial of their DRibble® cancer vaccine in women with triple negative breast cancer (TNBC) and men with advanced prostate cancer” said Dr. Bernard Fox, UbiVac co-founder and CEO.  He added, “After more than a decade of developing this disruptive vaccine technology, UbiVac is excited to be able to initiate clinical trials that combine some of the most promising science in the hope of improving outcomes of patients with these devastating diseases.” This bench-to-bedside research characterizing the immune response induced by the cancer vaccine was the result of a long-term collaboration between UbiVac and the Robert W. Franz Cancer Research Center at the Earle A. Chiles Research Institute, a component of Providence Health & Services.

About non-small cell lung cancer (NSCLC)

According to the World Health Organization, 1.59 million people died of lung cancer in 2016. In the US more men and women will die of lung cancer than any other cancer.

Checkpoint blockade and why the majority of patients with lung cancer are not cured

Anti-PD-1 agents (Nivolumab and Pembrolizumab) can provide substantial anti-cancer effects in patients with NSCLC. Unfortunately, the majority of patients fail to respond and many who experience regression ultimately progress and die of their disease. Since anti-PD-1 works by taking the brakes off the immune system, patients lacking an immune response against their cancer fail to respond. Further, it is hypothesized that patients who have an immune response against only a limited number of cancer “targets” may experience an initial tumor regression, but ultimately the tumor will continue to grow as it evades the limited immune response. UbiVac believes that inducing immunity against a large number of cancer targets (antigens) found in lung cancer is required in order to improve response rates to anti-PD-1 therapy and potentially cure patients of their lung cancer. These data, presented in the ASCO abstract, further support that UbiVac’s patented DRibble® vaccine technology can accomplish this task.

UbiVac’s strategy to induce broad anti-cancer immunity and improve patient outcomes

UbiVac’s patented platform technology is based on autophagy, the discovery of which was recognized with the 2016 Nobel Prize in Physiology or Medicine, and provided paradigm changing results in animal models which led to a series of clinical trials. Results of these clinical studies, document that UbiVac’s lead DRibble® cancer vaccine, DPV-001, is inducing and/or boosting the immune system of patients to recognize and potentially destroy their cancer. This ability to turn on the immune system to recognize cancer is a disruptive first step for the immuno-oncology sector, as only patients with pre-existing immunity are expected to respond to checkpoint blockade (anti-PD-1). Several leaders in the field have suggested that many or most patients with cancer lack anti-cancer immunity, limiting the effectiveness of anti-PD-1. Since UbiVac’s lead agent, DPV-001, a novel, 100+ antigen vaccine-based immunotherapy has induced or boosted broad anti-cancer in all patients studied to date, UbiVac’s next step is to combine this vaccine with anti-PD-1 antibodies that can overcome cancers ability to block cancer killer cells from destroying cancer.

UbiVac’s DPV-001 DRibble vaccine:  Ideal for combination immunotherapy

UbiVac’s DRibble technology has been formulated as the ideal companion for combination immunotherapy, and is complimentary to the pipelines of major pharmaceutical companies currently developing immuno-oncology therapies. In addition to the phase II trial in NSCLC, UbiVac’s technology already is in a clinical trial for men with prostate cancer and will soon open a combination immunotherapy trial with for patients with advanced triple negative breast cancer.

###

Contact: info@ubivac.com

Award Number R44CA121612 from the National Cancer Institute supported the research and clinical trial of DPV-001 in patients with NSCLC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a Phase II randomized multi-center adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.

By | June 2nd, 2017|Categories: News Releases, Press|0 Comments

UbiVac CEO Addresses International Symposium on Immunotherapy

May 12, 2017

Portland, Ore.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the International Symposium on Immunotherapy held 12-13 May at the Royal Society, London, England.

During his remarks, Dr. Fox will present positive results from the recently completed randomized, multi-center, Phase II clinical trial of UbiVac’s DPV-001 as adjuvant therapy for non-small cell lung cancer. His presentation detailed the process of exploiting autophagy to induce broad anti-cancer immunity in mice and humans.

UbiVac’s DRibble immunotherapy (DPV-001) is a first in class technology that combines more than 100 cancer targets including at least 13 National Cancer Institute (NCI) prioritized cancer antigens. DRibble vaccines are a disruptive technology able to overcome tolerance and induce or boost broad anti-cancer immunity. Since a pre-existing anti-cancer immune response is required for response to checkpoint blockade, UbiVac believes that DRibble technology is the ideal companion for combination immunotherapy providing a needed component to boost effectiveness of the pipeline of co-stimulatory and checkpoint antibodies that are approved or currently under development.

Preparing his remarks, Dr. Fox commented: “I am privileged and humbled to have been selected to do this, and to think that I will be speaking in the same hall where Darwin spoke.” Dr. Fox’s remarks comprise the Royal Society’s Holbrook Kohrt memorial lecture. Holbrook Kohrt, MD, PhD, (1977-2016), was an assistant professor at the Stanford University School of Medicine renowned for his clinical trials research examining novel immunologic approaches and his translational research on novel therapies to enhance antitumor immunity.

###

Award Number R44CA121612 from the National Cancer Institute supports the research and clinical trial of DPV-001 in patients with NSCLC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 recently completed a Phase II randomized multi-center adjuvant study for non-small cell lung cancer that documented efficacy for induction or boosting of broad anti-cancer immunity. Based on these data UbiVac is planning to open a phase Ib/II study of DPV-001 + anti-OX40 in patients with advanced cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.

By | May 12th, 2017|Categories: News Releases, Press|0 Comments

UbiVac Releases New Lung Cancer Clinical Trial Data: DPV-001 Vaccine Induces Broad Immunity Against Lung Cancer

Vienna, Austria.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a vaccine that educates the immune system to recognize and destroy cancer, is releasing new data at the 17th World Conference on Lung Cancer (WCLC), a meeting of the International Association for the Study of Lung Cancer (IASLC) held December 4-7 in Vienna. Rachel Sanborn, M.D., principal investigator for the US National Cancer Institute (NCI)-supported study, has documented the ability of UbiVac’s DRibble® cancer vaccine, DPV-001, to induce immunity against a spectrum of antigens that are over-expressed in NSCLC and associated with reduced survival.

Dr. Sanborn’s work suggests that vaccination with DPV-001 might improve response rates and durability of response to checkpoint blockade therapy in the majority of patients who lack effective anti-cancer immunity. DPV-001, a 100-plus antigen, vaccine-based immunotherapy has induced or boosted broad anti-cancer responses in all patients studied to date.

UbiVac’s research findings include results of its randomized phase II adjuvant clinical trial in patients with definitively-treated stage III non-small cell lung cancer (NSCLC), the most common type of lung cancer. “Induction of immunity against these genes commonly over-expressed in NSCLC is an exciting first step,” said Dr. Sanborn, “It suggests that combining DPV-001 vaccination with checkpoint blockade could increase response rates in the majority of patients with NSCLC that lack apparent anti-cancer immunity.” Evaluation of DPV-001-induced T cell responses is continuing.

Dr. Sanborn also is reporting results of initial studies showing that vaccinated patients generated CD4 and CD8 T cell immunity against lung cancer cells. “These data correlate with our preclinical studies showing DRibble® vaccine-induced T cell responses against cancer,” said Dr. Hong-Ming Hu, UbiVac co-founder and chief scientific officer. He added, “The DRibble vaccine could be an important addition to treatment options for many lung cancer patients.”

According to the World Health Organization, 1.59 million people will die of lung cancer in 2016. In the US more men and women will die of lung cancer than any other cancer.

UbiVac co-founder and CEO Dr. Bernard A. Fox provides additional insight. “Anti-PD-1 agents such as Nivolumab and Pembrolizumab can achieve substantial anti-cancer effects in patients with NSCLC. Unfortunately, the majority of patients fail to respond, and many who experience regression ultimately progress and die of their disease,” he notes.

“Since anti-PD-1 works by taking the brakes off of the immune system, patients lacking an immune response against their cancer fail to respond. Further, it is hypothesized that patients who have an immune response against only a limited number of cancer ‘targets’ can experience an initial tumor regression, but ultimately the tumor will continue to grow as it evades the limited immune response. UbiVac believes that inducing immunity against a large number of cancer antigens found in lung cancer is required to improve response rates to anti-PD-1 therapy and potentially cure patients.”

UbiVac’s patented platform technology is based on autophagy, a discovery that has provided paradigm changing results in animal models and has led to a series of clinical trials. Results of these clinical studies, including those presented by Dr. Sanborn at WCLC, document the potential for UbiVac’s lead vaccine to induce and/or boost the immune system of patients sufficiently to recognize and potentially destroy their cancer.

 

This ability to activate the immune system to recognize cancer is a disruptive first step for the immuno-oncology sector because only patients with pre-existing immunity are expected to respond to checkpoint blockade therapy. Several leaders in the field have suggested that many or most patients with cancer lack anti-cancer immunity, limiting the effectiveness of this therapy. UbiVac’s DPV-001, a 100+ antigen vaccine-based immunotherapy has induced or boosted broad anti-cancer responses in all patients studied to date. UbiVac’s next step is to combine DPV-001 with anti-PD-1 antibodies that can overcome cancer.

UbiVac’s DRibble technology has been formulated as the ideal companion for combination immunotherapy, and is complimentary to the pipelines of major pharmaceutical companies currently developing immuno-oncology therapies. In addition to the phase II trial in NSCLC, UbiVac’s technology is in a clinical trial for men with prostate cancer and plans to open a trial for patients with breast cancer. UbiVac recently expanded its laboratory and office facilities in Portland, Oregon with a second location that provides more than 15,000 square feet for manufacturing DPV-001 and staff additions necessary to further advance the company’s technology.

###

Contact: Patricia Pearson, ppearson@ubivac.com

 

Award Number R44CA121612 from the National Cancer Institute supports the research and clinical trial of DPV-001 in patients with NSCLC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a Phase II randomized multi-center adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.

The International Association for the Study of Lung Cancer’s (IASLC), World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries to discuss the latest developments in thoracic malignancy research. Attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses and allied health professionals and patients.

By | December 8th, 2016|Categories: News Releases, Press|0 Comments

UbiVac founder to open major cancer conference in Hong Kong

Hong Kong, China.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company whose lead product educates the immune system to recognize and destroy cancer, announces that its co-founder and CEO, Bernard A. Fox, PhD, will address the 21st Annual Scientific Symposium of the Hong Kong Cancer Institute on November 19th in Hong Kong.

Symposium participants include internationally recognized experts in immunotherapy from Europe, the USA and Asia. Dr. Fox will provide opening remarks with a lecture covering the biology of immunotherapy, cancer vaccines and immune checkpoint therapy.

He also will detail UbiVac’s DRibble immunotherapy (DPV-001), a first in class technology that combines more than 100 cancer targets, DAMPs and TLR agonist activity in a DC-targeted microvesicle. Ongoing Phase II clinical trials confirm that DRibble is novel and can help induce immunity against cancer.

Much of the symposium will focus on checkpoint therapy, biomarkers and combination strategies. Checkpoint therapy has provided a significant survival advantage over chemotherapy for a number of cancers. However, the majority of patients fail to obtain an objective response and ultimately progress and die of their disease.

It has been proposed that these patients either lack an anti-cancer immune response or have an immune response against a limited number of antigens, which the cancer cells can down-regulate and thus evade immune detection. UbiVac believes that by inducing immunity against a larger number of cancer antigens it will be more difficult for cancer to evade immune-mediated destruction.

Because DPV-001 induces and or boosts immunity against a large number of cancer antigens, UbiVac believes that its DRibble technology is the ideal companion for combination immunotherapy. It also is complimentary to the pipelines of major pharmaceutical companies developing immuno-oncology therapies. An ongoing, NCI-supported, randomized, multi-center Phase II clinical trial of DPV-001 is providing additional evaluation of its therapeutic effects.

According to Dr. Fox, UbiVac’s technology also is in a clinical trial for men with prostate cancer, and a trial for patients with breast cancer will open soon.

Award Number R44CA121612 from the National Cancer Institute supports the ongoing research and clinical trial of DPV-001.

###

Contact: Patricia Pearson, ppearson@ubivac.com

UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a Phase II randomized multi-center adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.

By | November 20th, 2016|Categories: News Releases, Press|0 Comments

Positive Immune Response Data for Patients Receiving DPV-001 Presented by UbiVac at Society for Immunotherapy of Cancer Meeting

Washington, D.C.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a vaccine that educates the immune system to recognize and destroy cancer, is presenting new data at the 31st Annual meeting of the Society for Immunotherapy of Cancer (SITC) November 9-13 in National Harbor, Maryland. UbiVac presentations are detailing results of its adjuvant clinical trial in non-small cell lung cancer (NSCLC), the most common type of lung cancer, and efforts to develop a combination immunotherapy for anaplastic thyroid cancer.

Dr. Christopher Paustian, a scientist at UbiVac, is presenting preliminary results documenting the ability of UbiVac’s DRibble® cancer vaccine, DPV-001, to induce CD4 and CD8 T cell immunity. “These are important data that also correlate with our findings in preclinical animal models,” Dr. Bernard Fox, UbiVac co-founder and CEO, said. “The field has been looking for a means to generate this type of anti-cancer T cell immunity and now we have early data confirming that the DRibble® vaccine does that in patients with NSCLC.”

Also at the SITC conference, Tarsem Moudgil, a scientist at the Earle A. Chiles Research Institute (EACRI) located within the Providence Cancer Center in Portland, Oregon, is summarizing efforts to characterize the immune response generated against thyroid cancers and the collaborative effort with UbiVac to develop a DRibble® vaccine for patients with this particular type of cancer. Anaplastic thyroid cancer, while rare, is highly aggressive and represents an unmet medical need.

In addition, Tyler Hulett, an Oregon Health and Science University PhD student working at the Earle A. Chiles Research Institute is receiving a SITC award for his presentation showing that mice receiving the DRibble® cancer vaccine induced CD8 T cell responses against both mutated and non-mutated epitopes, and providing examples of how T cells against both types of epitopes can recognize cancer cells.

“This is further documentation that UbiVac’s DRibble® platform technology induces T cell immunity against cancer,” said Dr. Hong-Ming Hu, UbiVac co-founder and CSO. “This information firmly supports the clinical application of DRibble® vaccines for the majority of patients with cancer who lack anti-cancer immunity”.

UbiVac’s DRibble technology has been formulated as the ideal companion for combination immunotherapy, and is complimentary to the pipelines of major pharmaceutical companies currently developing immuno-oncology therapies. In addition to the phase II trial in NSCLC, UbiVac’s technology already is in a clinical trial for men with prostate cancer and will soon open a trial for patients with breast cancer. UbiVac recently expanded its laboratory and office facilities in Portland, Oregon with a second location that provides more than 15,000 square feet for manufacturing and staff additions necessary to make further advance the company’s technology.

Award Number R44CA121612 from the National Cancer Institute supported the research and clinical trial of DPV-001 in patients with NSCLC.

###

 

Contact: Patricia Pearson, ppearson@ubivac.com

 

UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a Phase II randomized multi-center adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.

The Society for Immunotherapy of Cancer (SITC), is the world’s leading member-driven organization dedicated to professionals in the field of cancer immunotherapy. Its annual meeting assembles influential leaders including than 2,500 experts in basic, clinical and translational cancer immunotherapy research and clinical care, as well as nurses, pharmacists, interested patients and patient advocacy organizations.

By | November 14th, 2016|Categories: News Releases, Press, Uncategorized|0 Comments

UbiVac CEO to address World Life Science Conference in Beijing

Beijing, China.– UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder and CEO, Bernard A. Fox, PhD, will address the World Life Science Conference in Beijing and co-chair a session on November 2nd entitled Clinical Medicine: Immunotherapy and Biotherapy. Professor Zhigang Tian, president of the Chinese Society for Immunology, will co-chair the session.

Conference speakers include 13 Nobel Laureates and 400 top professors from around the world. Dr. Fox will provide his perspective on immunoscore/ Immunoprofiling and combination immunotherapy including vaccines. His remarks will include insights gained during more than 30 years of research in cancer immunotherapy including his participation in the Society for Immunotherapy leading to the global Immunoscore project. He also will discuss how UbiVac’s DRibble immunotherapy (DPV-001) might be used to induce immunity in the majority of patients with cancer who lack apparent anticancer immunity.

DPV-001 is a first in class technology that combines more than 100 cancer targets, DAMPs and TLR agonist activity in a DC-targeted microvesicle. Phase II clinical trials have confirmed that DRibble technology is novel and can help induce immunity against cancer.

UbiVac believes that DRibble technology is the ideal companion for combination immunotherapy, and is complimentary to the pipelines of major pharmaceutical companies currently developing immuno-oncology therapies. DPV-001 currently is being evaluated in an NCI-supported, randomized, multi-center Phase II clinical trial.

In addition, UbiVac’s technology already is in a clinical trial for men with prostate cancer and will soon open a trial for patients with breast cancer.

“We are pleased to participate in this important conference and to be part of advancing the task of finding a cure for cancer,” Dr. Fox said. Recently UbiVac expanded its laboratory and office facilities in Portland, Oregon with a second location that provides more than 15,000 square feet for manufacturing and staff additions necessary to make further advance the company’s technology.

Award Number R44CA121612 from the National Cancer Institute supports the ongoing research and clinical trial of DPV-001.

###

 

Contact: Patricia Pearson, ppearson@ubivac.com,

UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a Phase II randomized multi-center adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.

By | November 2nd, 2016|Categories: News Releases, Press, Uncategorized|0 Comments

Portland’s UbiVac To Brief International Immuno-Oncology Forum in Chicago

Portland, Ore.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the 2nd Annual 2016 Sachs Immuno-Oncology BD&L and Investment Forum on June 3 in Chicago.

During his remarks, Dr. Fox will detail UbiVac’s DRibble immunotherapy (DPV-001), a first in class technology that combines more than 100 cancer targets including at least 13 National Cancer Institute (NCI) prioritized cancer antigens. Ongoing Phase II clinical trials confirm that DRibble technology is novel and can help induce immunity against cancer.

UbiVac believes that DRibble technology is the ideal companion for combination immunotherapy, and fills a gap in the pipeline of major pharmaceutical companies currently developing immuno-oncology therapies. DPV-001 is currently being evaluated in an NCI-supported, randomized, multi-center Phase II clinical trial.

Dr. Fox will outline positive early results documenting induction of immunity against a wide spectrum of cancer targets in patients with non-small cell lung cancer (NSCLC). “We are excited to report early results documenting DPV-001’s ability to educate the immune systems of patients so they can recognize their cancer,” Dr. Fox said.

UbiVac’s technology already is in a clinical trial for men with prostate cancer and will soon open for patients with breast cancer.

Award Number R44CA121612 from the National Cancer Institute supports the ongoing research and clinical trial of DPV-001.

The Sachs Immuno-Oncology: BD&L and Investment Forum, www.sachsforum.com brings together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. According to organizers, the one-day meeting is expected to draw about 250 delegates and will include 30 presentations by both listed and private biotechnology companies.

Sachs Associates is considered to have significant knowledge of key individuals operating within the European and global biotech field and, through this annual Forum, provides an effective platform for companies like UbiVac to gain recognition among research collaborators and funders.

By | June 2nd, 2016|Categories: Press|0 Comments

Oregon Cancer Researcher to Present Findings in Europe

UbiVac CEO Dr. Bernard A. Fox will address London meeting on developing anti-cancer immunotherapeutic drugs

Portland, Ore.—The European Medicines Agency (EMA) and the Cancer Drug Development Forum (CDDF) have selected Dr. Bernard A. Fox, PhD, president and chief executive officer, UbiVac, www.ubivac.com, to anchor a session at a major medical conference in London, England February 4-5, 2016.

Dr. Bernard A. Fox, PhD, president and CEO, UbiVac

Dr. Bernard A. Fox, PhD, president and CEO, UbiVac

Dr. Fox will provide his perspective on “Novel Biomarkers: Pitfalls, Limitations and Emerging Options.” His remarks will include insights gained during more than 30 years of research in cancer immunotherapy. He will be joined by representatives of the USA, Canada and eight, Europe-focused institutions and companies.

According to the CDDF, this joint, multi-stakeholder meeting has been called as a result of the rapid growth of immunotherapy-based medicinal products in oncology that are bringing important advances in patient care and considerably changing treatment options, particularly in melanoma and lung cancers.

Dr. Fox is an internationally respected expert in immunotherapy for the treatment of cancer. He was awarded a Visionary/Legacy award in 2015 from the Society for Immunotherapy of Cancer (SITC), an organization in which he served as past president.

“I applaud the organizers for this timely initiative to help highlight some of the challenges we all face,” Dr. Fox said. “Developing new and better biomarkers that will guide the application of innovative cancer immunotherapies is an undertaking that will benefit from global input. I look forward to participating.”

The two-day EMA-CDDF workshop (http://cddf.org/) in London will include academics, regulators and industry representatives.

###

Contact: Patricia Pearson, ppearson@ubivac.com, 503.887.1871

UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a Phase II randomized multi-center adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.

By | February 1st, 2016|Categories: Press|0 Comments

Immunotherapy Research Scientist Dr. Bernard Fox Receives International Award for Advancing Innovative Treatments to Cure Cancer

Washington DC—A Portland, Ore. specialist in the area of immunotherapy and immuno-oncology has been awarded the prestigious Visionary/Legacy Award by the Society for Immunotherapy of Cancer (SITC) at its 30th Anniversary Award Ceremony here. Dr. Bernard A. Fox, PhD, President and Chief Executive Officer, UbiVac, www.ubivac.com, and Harder Family Chair for Cancer Research, at the Earle A Chiles Research Institute, Providence Portland Cancer Center, was lauded for: “His role in advancing the science and application of cancer immunotherapy, his dedication to the SITC and for his distinguished record of service and leadership in the field.”

The awards ceremony was held November 7 with a reception at the Smithsonian National Air and Space Museum.

Dr. Bernard A. Fox, PhD, president and CEO, UbiVac

Dr. Bernard A. Fox, PhD, president and CEO, UbiVac

Dr. Fox co-founded Portland-based UbiVac in 2005, a clinical stage immuno-oncology company, engaged in the development of immunotherapies to combat cancer. In September UbiVac agreed to a collaboration with Johnson & Johnson Innovation to develop and test, in preclinical studies, a vaccine to intercept oral cancer.

Dr. Fox also serves on the board of directors for the Oregon Bioscience Association, is a past president of the SITC, and current chair of the World Immunotherapy Council, a consortium of national and international cancer immunotherapy organizations.

Internationally recognized for his contribution to the development of immunotherapies for various cancers, Dr. Fox has served on advisory boards for Astra Zeneca, Bristol-Meyers Squibb, Cell Genesys, EMD Serono, Janssen/Johnson and Johnson, Novartis, Pfizer, Aduro and others.

The Society for Immunotherapy for Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. Established in 1984, the non-profit entity has a growing constituency of academic, government, industry, clinical and basic scientists, and practitioners from around the world.

About UbiVac

UbiVac is a clinical stage Immuno-Oncology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a Phase II randomized multi-center adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.

###

By | November 10th, 2015|Categories: Press|0 Comments

UbiVac CEO Bernard A. Fox to Head Discussion on Immunotherapy and Translational Oncology at Providence Cancer Center

Portland, Ore.—Internationally known immuno-oncologist Bernard A. Fox, PhD, chief executive officer of UbiVac, www.ubivac.com , will be heading a panel of specialists speaking on October 20, 6:00 to 8:00 pm, at the Earle A. Chiles Research Institute (EACRI) at the Providence Cancer Center. Dr. Fox also is the Harder Family Chair for Cancer Research, member and chief, Laboratory of Molecular and Tumor Immunology at EACRI.

The presentation is sponsored by the Oregon Bioscience Association.

The panel will highlight advances in immuno-oncology therapy, one of the most promising areas making significant strides in cancer treatment today.

Panelists and colleagues joining Dr. Fox are:

  • Brendan Curti, M.D., director, genitourinary oncology research and biotherapy clinical program, EACRI;
  • Hong-Ming, PhD, chief, Laboratory of Cancer Immunology, EACRI, and chief scientific officer at UbiVac;
  • William Redmond, PhD, assistant member, Laboratory of Cancer Immunology, EACRI;
  • Andrew Weinberg, PhD, chief, Laboratory of Basic Immunology, EACRI and president and chief scientific officer, AgonOx;
  • Emmanuel Akporiaye, PhD, division chief of experimental biology, Sidra Medical and Research Center, Doha, Qatar, adjunct member, EACRI and chief executive officer, Veana Therapeutics.

The Earle A. Chiles Research Institute, Providence Cancer Center, is located at 819 NE 47th Avenue, Portland. Please make reservations via the Oregon Bioscience Association www.oregonbio.org.

About UbiVac

UbiVac is a clinical stage, Immuno-Oncology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a phase II randomized multicenter adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A Fox and Hong-Ming Hu, UviVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health and Science University, created UbiVac CMV to license sdCMV.

###

By | October 15th, 2015|Categories: Press|0 Comments

UbiVac Announces Collaboration with Johnson & Johnson Innovation

UbiVac Announces Collaboration with Johnson & Johnson Innovation to Develop and Test, in Preclinical Studies, a Vaccine to Intercept Oral Cancer

PORTLAND, OR., Sept. 29, 2015 /PRNewswire/ — UbiVac, www.ubivac.com, a privately held clinical stage Immuno-Oncology company, has announced today a collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.  The Johnson & Johnson Innovation Center in California facilitated the research agreement on behalf of the Janssen Disease Interception Accelerator.

Under the terms of the agreement, UbiVac will develop new preclinical and clinical versions of its proprietary DRibble® immunotherapy for use in preclinical studies of oral cancer. UbiVac will receive an upfront payment, plus additional financial commitments, contingent upon reaching certain pre-determined research, development and manufacturing milestones. In addition to funding the research, Janssen has an option for further development and licensing of the new DRibble immunotherapy.

Many oral cancers develop from oral leukoplakia, a white lesion that develops in the oral cavity and is estimated to affect 2 percent of the global population. The World Health Organization defines this as a potentially malignant condition, with 1 percent of lesions progressing to oral cancer annually. It is unknown if surgical excision eliminates the risk of developing oral cancer. Thus, development of an immunotherapy that induced broad anti-cancer immunity and inhibited oral leukoplakia from transforming into oral cancer would represent a paradigm shift for treating this disease.

“We are excited about this collaboration with Janssen to evaluate UbiVac’s DRibble technology as a potential approach for intercepting oral cancer,” Bernard A. Fox, chief executive officer, UbiVac said. “The development of a vaccine for cancer has long been a dream of UbiVac. This project provides a scientific partner and the resources that could make that dream a reality.”

About UbiVac.

UbiVac is a clinical stage Immuno-Oncology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a phase II randomized multicenter adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble®, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005, by Drs. Bernard A Fox and Hong-Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University, created UbiVac CMV to license sdCMV.

###

By | September 29th, 2015|Categories: Press|0 Comments

UbiVac CEO Presents at the China Center for Food and Drug International Exchange’s China Cancer Immunotherapy Workshop

Beijing, China—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, has announced that its co-founder and CEO, Bernard A. Fox, PhD, has been invited to share his views on the application of biomarkers to the development and regulatory considerations for cancer immunotherapy at the China Cancer Immunotherapy Workshop on June 23. UbiVac is based in Portland, Ore.

The program is organized by the China Center for Food and Drug International Exchange (CCFDIE), in cooperation with the Center for Drug Evaluation (CDE) of the China Food and Drug Administration (CFDA) and Chinese American Hematologist and Oncologist Network (CAHON). Representatives from regulatory agencies in the European Union (EU) and the United States (US), pharmaceutical industry, and academia will share their views and experiences on the topic. The audience will include oncologists, scientists, leaders in oncology drug development, and government officials.

During his presentation, Dr. Fox will discuss the evolving role and opportunities for “immune biomarkers” in development of and regulatory considerations for cancer immunotherapeutics. He will highlight current state-of-the-art immune biomarkers, including the strategies UbiVac is employing to evaluate patients enrolled in their clinical trials, and how these studies could soon be used to tailor combination immunotherapies.

Dr. Fox also will provide examples of how immune biomarker assays have identified positive early results with UbiVac’s lead product, documenting induction or boosting of immunity against a wide spectrum of cancer targets in patients with non-small cell lung cancer (NSCLC).

“By inducing immunity against a wide range of putative cancer antigens, DPV-001, UbiVac’s lead agent, fills a gap in the pipeline of major pharmaceutical companies,” Dr. Fox said. “Much current research is focused on taking the brakes off the immune system. However, it appears the immune system in many patients is not turned on and needs to be revved up. UbiVac’s targeted complex immunotherapy was developed to do just that.”

UbiVac’s strategy is to combine DPV-001 with anti-PD-1 to prime anti-cancer immunity in patients who lack anti-cancer immunity. UbiVac’s research suggests that in synergy with anti-PD-1 inhibitors or other agents it appears possible for DPV-001 to substantially increase the response rate; and thus the percentage of patients who obtain a complete response to treatment. Anti-PD-1 inhibitors are a new class of drugs that activate the immune system to attack tumors. UbiVac will initiate a clinical trial of DPV-001 and anti-PD-1 to further test this strategy in the second half of 2015.

UbiVac’s technology is being studied in a National Cancer Institute (NCI)-supported, randomized, multi-center, phase II clinical trial for patients with NSCLC. UbiVac’s DC-targeted complex immunotherapy also is in a pilot study for men with prostate cancer. A trial for patients with breast cancer will open in the second half of 2015.

The ongoing clinical research reported in this announcement is supported by the NCI of the National Institutes of Health (NIH) under Award Number R44CA121612. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the NIH.

UbiVac is a clinical stage immuno-oncology company engaged in research and development of therapeutic immunotherapies to combat cancer. Founded in Portland, Ore. In 2005, it is a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute at Providence Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University, created UbiVac CMV Inc., to license a disabled cytomegalovirus (CMV) vector technology for use as a vaccine. This technology is actively being developed in collaboration with other research partners. The company’s co-founder, president and CEO, Bernard A. Fox, PhD, holds the Harder Family Endowed Chair for Cancer Research and is member and chief, Laboratory of Molecular and Tumor Immunology at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center.

###

By | June 22nd, 2015|Categories: Press|0 Comments

Portland’s UbiVac To Detail Progress With New Cancer Therapy at International Immuno-Oncology Forum in Chicago

Portland, Ore.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the 2015 Sachs Immuno-Oncology BD&L and Investment Forum on May 29 in Chicago.

During his remarks, Dr. Fox will detail UbiVac’s DRibble immunotherapy (DPV-001), a first in class technology that combines more than 100 cancer targets including at least 13 National Cancer Institute (NCI) prioritized cancer antigens. Research suggests that DRibble technology is novel and can overcome tolerance; inducing immunity against cancer. UbiVac believes that DRibble technology is the ideal companion for combination immunotherapy and fills a gap in the pipeline of all major pharmaceutical companies currently in the immuno-oncology space. UbiVac’s lead candidate, DPV-001, is currently in an NCI-supported randomized multi-center Phase II clinical trial.

Dr. Fox will outline positive early results documenting induction of immunity against a wide spectrum of cancer targets in patients with non-small cell lung cancer (NSCLC). “We are excited that early results document that DPV-001 is educating the immune system of patients so they can recognize their cancer, Dr. Fox said. He added, “UbiVac is already planning a 270-300 patient phase I/II trial that will combine DPV-001 with Opdivo, recently approved by the US FDA for patients with metastatic squamous NSCLC.” Based on animal studies, Fox believes the combination of Opdivo and DPV-001 will substantially increase the response rate and improve overall survival. UbiVac’s technology is already in a clinical trial for men with prostate cancer and will soon open for patients with breast cancer.

Award Number R44CA121612 from the National Cancer Institute supports the ongoing research and clinical trial of DPV-001.

The Sachs Immuno-Oncology: BD&L and Investment Forum, www.sachsforum.com is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharmaceutical and biotechnology to facilitate partnering, funding and investment. The one-day meeting is expected to draw about 200 delegates, and an online meeting system will make the event transactional. Tracks will include presentations by both listed and private biotechnology companies.

Sachs Associates is considered to have significant knowledge of key individuals operating within the European and global biotech field, putting the firm at the forefront of the industry and, through this annual Forum, providing an effective platform for companies like UbiVac to gain recognition among collaborators and funders.

UbiVac is a clinical stage immuno-oncology company engaged in research and development of therapeutic immunotherapies to combat cancer. Founded in Portland, Ore. In 2005, it is a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute at Providence Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University, created UbiVac CMV Inc., to license a disabled cytomegalovirus (CMV) vector technology for use as a vaccine. This technology is actively being developed in collaboration with other research partners. The company’s co-founder, president and CEO, Bernard A. Fox, PhD, holds the Harder Family Endowed Chair for Cancer Research and is member and Chief, Laboratory of Molecular and Tumor Immunology at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center.

###

By | May 26th, 2015|Categories: News Releases, Press|0 Comments

Portland’s UbiVac Announces Two International Experts in Pharmacology to Their Advisory Board

Portland, Ore.—UbiVac, www.ubivac.com, a spinout biotechnology company of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute at Providence Portland Medical Center, has announced two internationally renowned research scientists to their advisory board.

Ashok K. Batra, MD, FRCS, FACS, MBA and Paul E. Freiman, BS and honorary doctorate from Arnold & Marie Switzer College of Pharmacy, have joined UbiVac’s advisory board, adding their considerable expertise in pharmaceutical science.

Dr. Batra has more than 30 years of international experience in academic medicine, scientific research, medical management, clinical trials and regulatory policy. He holds an MD from Delhi University, India and received general surgery training in the United Kingdom and is a Fellow of the Royal College of Surgeons, Glasgow, Scotland.

Dr. Batra received training in urology and neuro-urology training at UPENN, UCSF and Temple Universities in the US. He is a board certified urologist and a Fellow of the American College of Surgeons. He earned an MBA from Binghampton University, New York.

A Division Director of Clinical Evaluations and Pharmacology Toxicology at OCTGT, CBER, he was part of the Federal Drug Administration (FDA) that regulated cancer vaccines, immunotherapies, stem cell therapies, and gene therapies. Prior to that he was adjunct professor and division director of neuro-urology, female and reconstructive urology at SUNY, Syracuse.

At present Dr. Batra is managing director of USBPC Group LLC that provides consultation services, scientific advice and expert opinion on biotechnology, pharmaceutical and medical device development.

Freiman has extensive pharmaceutical and biotechnology industry operating experience as a board member and chief executive officer of private and publicly traded companies.

He is a pharmacist and is currently an independent pharmaceutical and biotechnology industry consultant. He serves as chairman of Chronix BioMedical and is a member of the NovaBay Pharmaceutical Board of Directors.

Before that Freiman served on the boards of Otsuka America, Inc. and several biotechnology companies based in the US and Singapore. He also was a partner of Burrill Brasil Investmentos based in Rio de Janiero and president and chief executive officer of Neurobiological Technologies, Inc. and a member of its board of directors.

Freiman was chairman and chief executive officer of Syntex Corporation that was sold to the Roche Group for $5.3 billion during his tenure. He is credited with much of the marketing success of Syntex’s lead product, Naprosyn, and was responsible for moving the product to over-the-counter status, marketed as Aleve. Aleve currently generates approximately $400 million in annual revenues worldwide.

Frieman served on the board of the Pharmaceutical Research and Manufacturers Association of America (PhRMA) and was its chairman. He also served on industry task forces, nationally and internationally and was chairman of the University of California Foundation, the United Way of Silicon Valley and a number of not-for-profit organizations through the years.

UbiVac is a clinical stage biotechnology company engaged in research and development of therapeutic immunotherapies to combat cancer. Founded in Portland, Ore. In 2005, it is a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute at Providence Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University, created UbiVac CMV Inc., to license a disabled cytomegalovirus (CMV) vector technology for use as a vaccine. This technology is actively being developed in collaboration with other research partners.

###

By | April 23rd, 2015|Categories: Press|0 Comments

Portland-based Immunotherapy Research Scientist Dr. Bernard Fox To Address Medical Conference in Tokyo

Portland, Ore—Bernard A. Fox, PhD, president and chief executive officer of Ubivac, www.ubivac.com, a spinout biotechnology company of the Robert W. Franz Cancer and Research Center within the Earle A. Chiles Research Institute at Providence Portland Medical Center, will present at the International joint COS-CAHON-SITC Workshop on Cancer Immunotherapy 2015 on April 25. The conference will be held at the International Conference Center of National Taiwan University, Taipei, Taiwan.

The title of Dr. Fox’s talk will be “The Transformation of Oncology: A Strategic Review of Immunoscore and Immunotherapy.”

Before the conference, April 22, Dr. Fox will be addressing the Institute for Advanced Medical Research at Kejo University in Tokyo, Japan on the same topic.

At present UbiVac has a pipeline of immunotherapeutic drugs in preclinical and clinical Phase 1 and II trials. The company’s lead product, DRibble, DPV-001, is currently enrolling patients with non-small cell lunch cancer (NSCLC), in an NCI-funded multi-center Phase II trial. DPV-001 is also being used in a pilot study for patients with advanced prostate cancer. A Phase Ii trial in breast cancer is planned for later this quarter as well as a combined Phase 1/II trial for Mesothelioma in the fourth quarter this year. Other clinical trials are planned for advanced NSCLC, head and neck squamous cell cancer and advanced HPV-related cancers.

Other UbiVac immunotherapeutic products include Nano Particle, DPV-003, and CMV Vector, also at various stages of development.

“There is a new paradigm for treating cancer that not only complements current therapies, but offers a clear potential for a cure,” Dr. Fox commented. “We are very encouraged by the results of the trials thus far.”

Dr. Fox is the Harder Family Endowed Chair for Cancer Research at the Providence Cancer Center, the chair of the World Immunotherapy Council, a consortium of 22 national and international cancer immunotherapy organizations and a board member of the Oregon Bioscience Association.

The information presented in this news release is supported by the NCI of the National Institutes of Health under Award Numbers R44CA121612 and U43CAI65048. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the National Institutes of Health.

UbiVac is a clinical stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer and infectious diseases. Founded in Portland, Ore. In 2005, it is a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute at Providence Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University, created UbiVac CMV Inc., to license a disable cytomegalovirus (CMV) vector technology for use as a vaccine This technology is actively being developed in collaboration with other research partners.

###

By | April 21st, 2015|Categories: Press|0 Comments

UbiVac and collaborators have three presentations at Society for Immunotherapy of Cancer meeting

Washington DC, — UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced additional details on UbiVac’s first-in-class autophagosome DRibble vaccine, DPV-001, in three presentations at the 28th Annual meeting of the Society for Immunotherapy of Cancer (SITC) outside of Washington DC, from November 7-10. Dr. Traci Hilton with UbiVac, presented data from gene expression profiling and mass spec analysis of the vaccine and described the Dendritic cell targeting molecule that delivers the autophagosome packets to cross-presenting antigen-presenting cells.

http://www.immunotherapyofcancer.org/content/1/S1/P260

Dr. Rieneke van de Ven, in work performed at the Earle A. Chiles Research Institute (EACRI) and partially funded by the Dutch Cancer Society, presented a series of studies using a component of DPV-001, that shares on average 37.1 overexpressed genes with prostate cancer samples, to successfully monitor the development of anti-cancer T cell responses in men on a prostate cancer vaccine study.

http://www.immunotherapyofcancer.org/content/1/S1/P113

Tarsem Moudgil summarized EACRI and Providence Cancer Center (PCC) efforts to develop effective immunotherapy for squamous cell carcinoma of the head and neck. In addition to T cell function studies and preliminary immunoscore studies, Moudgil reported the percentage of head and neck squamous cell cancers (HNSCC) that have either a genomic amplification or increased gene expression profile for 17 HNSCC antigens that are also up-regulated in DPV-001. These findings suggest that the DPV-001 vaccine should be evaluated as a vaccine for HNSCC.

http://www.immunotherapyofcancer.org/content/1/S1/P262

Dr. Michael Neuberger reported that cytomegalovirus vectors containing a melanoma antigen could provide potent immunity and protect mice from a difficult to treat melanoma. Importantly it induced a strong antibody response against the tumor antigen that, with time, evolved to include an anti-cancer T cell response. This is in contrast to “gold standard” vaccine strategies that induce primarily T cell responses.

http://www.immunotherapyofcancer.org/content/1/S1/P271

Dr. Hong-Ming Hu, UbiVac co-founder and CSO, stated “these CMV data are exciting because they provides us with an opportunity to combine different vaccine strategies and induce a spectrum of anti-cancer immunity.” UbiVac continues to work closely with leaders in CMV immunology/biology, Drs. Ann Hill and Chris Snyder, co-founders of UbiVac-CMV, as well as collaborators at the EACRI and PCC on the development of these and other strategies as effective treatments for patients with cancer.

UbiVac, spun-out from the Providence Health System in 2005, and recently was judged by Oregon CEOs as the top “Presenting Company” at the Oregon Bioscience Association annual meeting.

By | November 11th, 2013|Categories: Press|0 Comments

UbiVac Opens Trial of Next Generation Lung Cancer Vaccine

SYDNEY, Nov. 5, 2013 /PRNewswire/ — UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced the results of a Phase I clinical trial and the initiation of a Phase II clinical trial of its first-in-class autophagosome DRibble vaccine, DPV-001, in two presentations at the 15th World Conference for Lung Cancer, in Sydney, from October 27-30. The multicenter, randomized Phase II clinical trial of DPV-001 is supported by a US$3.4 million National Cancer Institute (NCI) grant and will involve 48 individuals with definitively treated stage IIIA/B non-small cell lung cancer (NSCLC). A description of DPV-001, an “off-the-shelf vaccine,” was presented by Dr. Helen Ross, Mayo Clinic Arizona, in an oral session (abstract #O-08.01). This next generation vaccine contains a system for targeting to dendritic cells, at least 9 cancer antigens prioritized by an NCI advisory panel and 5 toll-like receptor agonists to boost immunity. “Patients with locally advanced lung cancer still have a very high risk of cancer returning despite our most aggressive treatments,” said Dr. Rachel Sanborn, the trial’s principal investigator and the Co-Director of Thoracic Oncology, Providence Cancer Center, Portland, Oregon. “This novel vaccine approach may help the immune system recognize and fight remaining cancer cells.” In a presentation of the Phase 1 trial in patients with Stage IV NSCLC, the authors reported that immune responses were detected in a majority of the evaluable patients (abstract # P-3.11-032).

“UbiVac is excited to pioneer this first-in-class vaccine technology to patients with NSCLC,” said Dr. Hong-Ming Hu, inventor of autophagosome DRibble technology, Co-founder and CSO of UbiVac. “In addition to lung cancer, UbiVac is actively pursuing the application of this technology, with our partners and collaborators, for the treatment of head and neck, hepatocellular, prostate, colon and breast cancer.”

UbiVac, spun-out from the Providence Health System in 2005, recently was judged by Oregon CEOs as the top “Presenting Company” at the Oregon Bioscience Association annual meeting has three vaccine platform technologies under development: DRibbles, a nanotechnology platform and a disabled cytomegalovirus (CMV) vector platform.

The ongoing activities reported in this release are supported by the NCI of the National Institutes of Health under Award Numbers R44CA121612 and U43CA165048. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the National Institutes of Health.

By | November 5th, 2013|Categories: Press|0 Comments

Oregon Bioscience company UbiVac awarded top “presenting company” honor

Beating 15 other startups, Oregon company CEOs judge UbiVac as best new bioscience company at the Oregon Bioscience Association’s annual conference, as the growing firm seeks to initiate its second clinical trial as early as 2015.

(Portland, Ore.) — UbiVac , a privately-held, clinical stage immunotherapy company, founded and based in Portland, Oregon, won the top honors as the 2013 Presenting Company last week at the Oregon Bioscience Association’s (https://www.oregonbio.org/) annual meeting.  UbiVac won for its Product and Investment Potential presentation.

“UbiVac researches and develops therapeutic vaccines to combat cancer,” say company founder and internationally known immunologist Bernard A. Fox Ph.D. “Our company is unique because we have licensed platform technologies from three research Institutions in Oregon and are working with the inventors and National Cancer Institute-trained (NCI) clinical investigators to rapidly translate and evaluate the effectiveness of these immunotherapy strategies in patients with cancer.” The three local research institutions comprise Providence, Portland State University and Oregon Health & Science University.

“UbiVac is honored to be the recipient,” said Dr. Fox, UbiVac’s CEO. “We see this as further validation of our first-in-class agents, invented and produced in Portland, and our efforts to develop effective immunotherapy for patients with cancer.  In addition to our DRibble technology, the nanotech and disabled-CMV cancer vaccine platforms that UbiVac is developing hold great promise for improving outcomes of patients with cancer.”

He adds,  “It shows we have made an effective case about the value and the investment-worthiness of our first-in-class cancer immunotherapies.”

“UbiVac has been and remains an important member of Oregon’s growing bio-economy,” said Oregon Bio’s (https://www.oregonbio.org/) Executive Director Dennis McNannay. “It has been extraordinarily successful in collaborations with both local and international researchers as well as garnering national attention and funding. UbiVac is a real, local success story in many ways.”
In addition to industry validation, UbiVac as the overall winner will also receive $1,500 of donated legal services from Alleman Hall McCoy Russell & Tuttle, LLP (http://www.ahmrt.com/), an intellectual property lawfirm with patent attorneys in Portland, Oregon and Kobe, Japan.

According to the company, Ubivac recently received an NCI Phase l grant from the federal SBIR (Small Business Innovation Research) to develop a nanotechnology-based vaccine for HPV-induced cancers, including cervical and HPV, and cancers of the upper body such as Head Neck Squamous Cell Carcinoma. “The technology, published by collaborators in the prestigious journal Nature Nanotechnology, is an exciting advance in nano-based vaccines, with this project as a collaboration between the Portland State University and the Earle A. Chiles Research Institute,” said Dr. Fox. He added that in their efforts, researchers will seek to initiate a Phase I clinical trial in 2015.

Second and third place winners included Wellero and 13Therapeutics, respectively. Wellero ™ is part of, and backed financially by Cambia Health Solutions.

The company presentations were part of Oregon Bioscience Association’s 2013 annual conference (https://www.oregonbio.org/events/annual-conference-2013), which commenced last week and was themed ‘The Economics of Life Sciences. Keynote and featured speakers included nationally renowned thought leaders (https://www.oregonbio.org/keynote-speakers) in the innovation economy, product and therapeutic development, industry funding, scientific breakthrough research and health reform from companies and organizations such as The Salk Institute for Biological Studies, Galena Biopharma, Genentech, GNS Healthcare, Cambia Health Solutions, Zoomcare Inc., and Neolac.

Said Oregon Bioscience Association’s (https://www.oregonbio.org/) Executive Director, Dennis McNannay, “Attending company executives such as Dr. Fox met one-on-one with prospective investment partnering companies while learning more about the deep pool of research expertise, facilities and specialized equipment Oregon offers through its bioscience-based signature research institute, OTRADI, other signature research centers, and university-based programs.”

By | September 30th, 2013|Categories: Press|0 Comments

Autophagosome-enriched cancer vaccine strategy provides a novel non-genetic method to engineer leukocytes to express molecules that may augment cancer immunotherapy. (P4252)

Christopher Paustian,1Traci Hilton,2Rieneke Van De Ven,1Daniel Haley,3Chris Twitty,1Hong-Ming Hu,4Bernard Fox,1 and Sandra Aung2

1Molecular and Tumor Immunology, PPMC EACRI, Portland, OR 2UbiVac, Portland, OR 3Immunological Monitoring Lab, PPMC EACRI, Portland, OR 4Cancer Immunobiology, Earle A. Chiles Research Institute, Portland, OR

CD80 expression by APC provides signal 2, a critical element in priming T cell immune responses to antigen. As limited CD80 expression on APC can result in reduced immune responses, strategies that increase CD80 may have benefit. We report here that the autophagosome-enriched vaccine named DRibbles (DRiPs and SLiPs in Blebs), derived from human tumor cells transfected with a plasmid encoding huCD80, are highly efficient at transferring membrane proteins onto human PBMCs. When PBMCs were incubated with a DRibble vaccine derived from a CD80 expressing breast-tumor cell line, a significant increase in surface expression of CD80 was observed on PBMCs within 5 minutes (p<0.001). This effect was time and concentration-dependent and repeatable across multiple donors (N=5) in multiple experiments (N≥16). DRibble vaccine could transfer CD80 onto as high as 60-86.4% of monocytes and 41-86.1% of CD4+ T cells. Transfer of CD80 to CD8 T cells was substantially less effective. Transfer of membrane-associated proteins between leukocyte populations is a well-documented phenomenon, however, this is the first report of transfer of membrane-associated proteins from cell-free autophagosomes. Current efforts are investigating the functional properties associated with increased expression of CD80. Given the critical role of CD80 in augmenting immune responses this provides a novel strategy to further augment the response to DRibble vaccines, which are being explored in clinical trials.

By | May 3rd, 2013|Categories: Press|0 Comments